Answers are grounded in this paper and cite their sources.
Compound 37 showed comparable antirhinoviral activity to Win 54954 in vitro, though QSAR analysis failed to explain activity differences among analogs.
A variety of heterocyclic analogs of Win 54954 have been synthesized and tested in vitro against human rhinovirus type 14 (HRV-14) in a plaque reduction assay. The more active compounds were tested against 14 additional serotypes, and the concentration which inhibited 80% of the serotypes tested (MIC80) was measured. One compound, 37, exhibited activity comparable to Win 59454. Physicochemical as well as electrostatic parameters were calculated and the results subjected to a QSAR analysis in an effort to explain differences in activity observed between these compounds; however, no meaningful correlation with biological activity was found with any of these parameters.
No takes yet. Share an insight, caveat, or question.
Bailey et al. (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: